NasdaqGS:CGEMBiotechs
Why Cullinan Therapeutics (CGEM) Is Up 6.6% After Zipalertinib’s Positive Phase 3 Lung Cancer Data And What's Next
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics previously reported that the global Phase 3 REZILIENT3 trial of zipalertinib plus platinum-based chemotherapy in first-line EGFR exon 20 insertion non-small cell lung cancer met its primary endpoint, showing a statistically significant and clinically meaningful progression-free survival benefit with manageable safety.
This outcome positions zipalertinib, an investigational next-generation irreversible EGFR inhibitor, as a...